CN113677708A - 采用抗il13r抗体或其结合片段的治疗 - Google Patents

采用抗il13r抗体或其结合片段的治疗 Download PDF

Info

Publication number
CN113677708A
CN113677708A CN202080022235.4A CN202080022235A CN113677708A CN 113677708 A CN113677708 A CN 113677708A CN 202080022235 A CN202080022235 A CN 202080022235A CN 113677708 A CN113677708 A CN 113677708A
Authority
CN
China
Prior art keywords
ser
val
gly
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080022235.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Csl Co
Aslan Pharmaceuticals Pte Ltd
Original Assignee
Csl Co
Aslan Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Co, Aslan Pharmaceuticals Pte Ltd filed Critical Csl Co
Publication of CN113677708A publication Critical patent/CN113677708A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080022235.4A 2019-03-26 2020-03-26 采用抗il13r抗体或其结合片段的治疗 Pending CN113677708A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SG10201902713S 2019-03-26
SG10201902713S 2019-03-26
SG10201905063R 2019-06-03
SG10201905063R 2019-06-03
SG10201907597W 2019-08-16
SG10201907597W 2019-08-16
PCT/SG2020/050170 WO2020197502A1 (en) 2019-03-26 2020-03-26 Treatment employing anti-il-13r antibody or binding fragment thereof

Publications (1)

Publication Number Publication Date
CN113677708A true CN113677708A (zh) 2021-11-19

Family

ID=70228774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080022235.4A Pending CN113677708A (zh) 2019-03-26 2020-03-26 采用抗il13r抗体或其结合片段的治疗

Country Status (10)

Country Link
US (1) US20210277131A1 (enExample)
EP (1) EP3947457A1 (enExample)
JP (1) JP2022528324A (enExample)
KR (1) KR20210143788A (enExample)
CN (1) CN113677708A (enExample)
AU (1) AU2020247175A1 (enExample)
CA (1) CA3134495A1 (enExample)
IL (1) IL286603A (enExample)
SG (1) SG11202109545VA (enExample)
WO (1) WO2020197502A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en) * 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) * 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
TW202332466A (zh) * 2021-10-29 2023-08-16 新加坡商亞獅康私人有限公司 抗ｉｌ－１３ｒ抗體調配物
WO2023075702A1 (en) * 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
US20250163165A1 (en) * 2022-02-23 2025-05-22 Aslan Pharmaceuticals Pte Ltd Glycosylated form of anti-il13r antibody
JP2025529908A (ja) * 2022-08-26 2025-09-09 アスラン ファーマシューティカルズ ピーティーイー リミテッド 高濃度抗ｉｌ１３ｒ抗体製剤
WO2025095864A1 (en) * 2023-11-02 2025-05-08 Aslan Pharmaceuticals Pte Ltd Treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101141980A (zh) * 2004-06-09 2008-03-12 惠氏公司 针对人白介素-13的抗体及其用途
CN101588816A (zh) * 2006-10-19 2009-11-25 默克制药公司 白介素-13受体α1的高亲和性抗体拮抗物
CN101977935A (zh) * 2007-04-23 2011-02-16 惠氏公司 用于治疗和监测il-13相关病症的方法和组合物
WO2019004943A1 (en) * 2017-06-30 2019-01-03 Aslan Pharmaceuticals Pte Ltd METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
CA2468950A1 (en) 2001-11-27 2003-06-05 Mochida Pharmaceutical Co., Ltd. Anti-il13 receptor .alpha.1 neutralizing antibody
EP1576013A4 (en) 2002-03-22 2008-08-13 Amrad Operations Pty Ltd MONOCLONAL ANTIBODY AGAINST THE INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RA1)
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2068922B1 (en) * 2006-10-19 2012-06-27 CSL Limited Anti-il-13r alpha 1 antibodies and their uses thereof
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
WO2016109822A1 (en) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101141980A (zh) * 2004-06-09 2008-03-12 惠氏公司 针对人白介素-13的抗体及其用途
CN101588816A (zh) * 2006-10-19 2009-11-25 默克制药公司 白介素-13受体α1的高亲和性抗体拮抗物
CN101977935A (zh) * 2007-04-23 2011-02-16 惠氏公司 用于治疗和监测il-13相关病症的方法和组合物
WO2019004943A1 (en) * 2017-06-30 2019-01-03 Aslan Pharmaceuticals Pte Ltd METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POPOVIC, B.等: "Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2", JOURNAL OF MOLECULAR BIOLOGY, vol. 429, no. 2, pages 1 - 22 *

Also Published As

Publication number Publication date
AU2020247175A1 (en) 2021-10-14
EP3947457A1 (en) 2022-02-09
KR20210143788A (ko) 2021-11-29
SG11202109545VA (en) 2021-10-28
JP2022528324A (ja) 2022-06-10
WO2020197502A1 (en) 2020-10-01
CA3134495A1 (en) 2020-10-01
US20210277131A1 (en) 2021-09-09
IL286603A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CN113677708A (zh) 采用抗il13r抗体或其结合片段的治疗
JP6993992B2 (ja) 抗ｐｄ－１抗体、その産生方法及びその使用方法
US10370447B2 (en) Molecules with specificity for CD79 and CD22
US10618957B2 (en) Antibody molecules which bind CD79
CN112351797A (zh) 抗b7-h4抗体-药物偶联物及其医药用途
JP2016505633A (ja) ＴＮＦα抗原結合性タンパク質
CA2992372A1 (en) Antibody molecules which bind cd22
MX2014000739A (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada.
CN114292330A (zh) 结合cd45的抗体分子
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
WO2018210230A1 (zh) 一种pd-l1抗体药物组合物及其用途
TW202220702A (zh) 一種含抗體藥物偶聯物的醫藥組成物及其用途
JP2024012394A (ja) 抗ヒトｔｌｒ７抗体
CN111819196A (zh) 双特异性hiv-1中和抗体
CN115501347A (zh) 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途
WO2021009267A1 (en) Anti-pd-l1 antibodies
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
IL293753A (en) Biopharmaceutical preparations and related methods
WO2025235797A1 (en) Potent asgpr-binding heterobifunctional compounds comprising antibodies for the degradation of targeted proteins
TW202440159A (zh) 含有治療性抗體的藥物製劑及其用途
JP2025124594A (ja) 抗ｉｌ２７ｒ抗体およびその使用の方法
JP2025525829A (ja) 抗ｉｌ２７ｒ抗体およびその使用の方法
WO2024240171A1 (zh) 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途
TW202332466A (zh) 抗ｉｌ－１３ｒ抗體調配物
TW202434295A (zh) 一種靶向ｔｓｌｐ的單殖株抗體製劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211119